Prophylactic HIV-1 vaccine trials: past, present, and future
Authors:
- 20 December 2023
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 11 (2) , e117-e124
Abstract
No abstract availableKeywords
Funding Information
- Ragon Institute of MGH, MIT and Harvard
- Bill and Melinda Gates Foundation (INV-048656)
- Bill and Melinda Gates Foundation (INV-002377)
- National Institutes of Health (AI068614)
- National Institutes of Health (AI145801)
- National Institutes of Health (AI164556)
- National Institutes of Health (AI129797)
- National Institutes of Health (AI149670)
- National Institutes of Health (AI128751)
- National Institutes of Health (AI169615)
This publication has 67 references indexed in Scilit:
- Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodiesJournal of Experimental Medicine, 2013
- B-cell–lineage immunogen design in vaccine development with HIV-1 as a case studyNature Biotechnology, 2012
- Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingScience, 2011
- A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)PLOS ONE, 2011
- Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyThe Lancet Infectious Diseases, 2011
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Challenges in the development of an HIV-1 vaccineNature, 2008
- Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, ThailandThe Journal of Infectious Diseases, 2006